Form 4: CalciMedica CEO Rachel Leheny Plans Future Stock Purchase Under 10b5-1 Plan

CalciMedica, Inc. CEO and 10% owner Rachel Leheny has filed a Form 4 indicating a planned future purchase of 1,000 shares of common stock at $3.40 per share on July 21, 2025, under a Rule 10b5-1 trading plan.

Summary

• CalciMedica, Inc. CEO, Director, and 10% owner A. Rachel Leheny reported a planned acquisition of 1,000 shares of common stock.
• The transaction is scheduled for July 21, 2025, at a price of $3.40 per share.
• The purchase is being made indirectly by the Scheibler-Leheny Family Living Trust, which will hold 3,500 shares after this transaction.
• The filing indicates this transaction is pursuant to a Rule 10b5-1(c) plan, which allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information.
• Leheny's total beneficial ownership following the reported transaction includes 130,926 shares held directly, 3,500 shares held indirectly by the Scheibler-Leheny Family Living Trust, 1,000 shares held indirectly by spouse, 356,989 shares held indirectly by Valence Investments SPV IV, LLC, 66,228 shares held indirectly by Valence Investments SPV V, LLC, and 316,109 shares held indirectly by Valence Investments SPV VI, LLC, totaling 874,752 shares.

Sentiment

Score: 7

Explanation: The planned insider purchase by the CEO and a significant owner, even if small, generally indicates confidence in the company's future. The use of a 10b5-1 plan suggests a disciplined approach. However, the small size of the purchase relative to total holdings tempers the overall positive sentiment.

Positives

• A. Rachel Leheny, a key insider (CEO, Director, 10% Owner), is planning to purchase company stock, which can signal confidence in the company's future prospects.
• The purchase is being made under a Rule 10b5-1 plan, indicating a pre-planned transaction rather than a reaction to immediate news, which can be viewed as a disciplined approach to investing.

Negatives

• The planned purchase amount of 1,000 shares is relatively small compared to the insider's total beneficial ownership of 874,752 shares across various direct and indirect holdings.

Risks

• The future stock price of CalciMedica, Inc. may fluctuate, and there is no guarantee that the planned purchase price of $3.40 will be the lowest or highest price at which the stock trades.
• While a 10b5-1 plan is designed to mitigate insider trading concerns, it does not guarantee positive returns on the investment.

Future Outlook

The filing itself does not provide forward-looking statements or guidance beyond the planned transaction date. However, an insider purchase, even if pre-planned, can be interpreted as a positive signal regarding management's confidence in the company's future performance.

Industry Context

Insider purchases, particularly by a CEO and significant owner, are generally viewed positively by the market as they suggest management believes the stock is undervalued or has strong future prospects. This specific transaction, being a pre-planned 10b5-1 purchase, indicates a structured approach to increasing insider holdings rather than a reactive trade.

Comparison to Industry Standards

• Insider buying activity is a common indicator tracked by investors. While the size of this specific purchase (1,000 shares) is modest compared to the insider's total holdings, it aligns with standard practices for insiders to acquire shares, often through pre-arranged plans like 10b5-1, to demonstrate alignment with shareholder interests.
• There are no specific comparable companies, projects, or results mentioned in this Form 4 to provide a direct comparison of financial performance or operational outcomes.

Related Party Transactions

• The transaction involves an indirect acquisition by the Scheibler-Leheny Family Living Trust, which is a related party to the reporting person, A. Rachel Leheny.

Stakeholder Impact

• Shareholders may view the planned insider purchase as a positive signal of management's confidence in the company's value and future prospects.

Next Steps

• The planned acquisition of 1,000 shares of common stock is scheduled to occur on July 21, 2025.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, SEC Form 4, Insider Trading, Stock Purchase, Beneficial Ownership, CEO, Director, 10% Owner, Rule 10b5-1, Equity Securities